Keratoacanthoma - Keratoakantóm
☆ AI Dermatology — Free Service
Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Typický keratoakantóm (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) je častý kožný nádor, ktorý je známy rýchlym rastom a schopnosťou samovoľne regredovať. Typicky sa vyskytuje u starších mužov so svetlou pleťou a anamnézou poškodenia slnkom. Kým je chirurgické odstránenie pomocou excízie alebo Mohsovej mikrografickej chirurgie bežnou liečbou, existujú aj ďalšie možnosti liečby.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) je nádor nízkeho stupňa, ktorý vzniká v určitých kožných žľazách a pod mikroskopom vyzerá podobne ako squamous cell carcinoma (SCC). Prebieha diskusia o tom, či by KA mala byť klasifikovaná ako forma invazívneho SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) je druhým najčastejším typom rakoviny u ľudí, najmä u starších jedincov. Chirurgický zákrok sa zvyčajne používa na liečbu cSCC, ale pre niektorých pacientov, ktorí nemôžu podstúpiť operáciu alebo sa rozhodnú nepodstúpiť ju, je možné zvážiť iné možnosti, napríklad intralesiálnu liečbu. Použili sa tradičné intralesiálne liečby (methotrexate alebo 5-fluorouracil), ale výskum nových prístupov, ako je intralesiálna imunoterapia a onkolytická viroterapia, stále prebieha. Tu sa pozrieme na rôzne intralesiálne liečby cSCC, od klasických metód až po špičkové stratégie.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pod mikroskopom keratoakantóm (keratoacanthoma) veľmi pripomína spinocelulárny karcinóm. Zatiaľ čo niektorí patológovia klasifikujú keratoakantóm (keratoacanthoma) ako odlišnú entitu a nie ako malignitu, asi 6 % klinických a histologických prípadov keratoakantómu (keratoacanthoma) sa rozvinie do invazívnych a agresívnych skvamocelulárnych karcinómov.
○ Diagnostika a liečba
#Dermoscopy
#Skin biopsy